Therefore, we hypothesized that TA on the ICG-Glow NPs efficiently binds to EGFR, CXCR4, FASN, and other oncoproteins (Figure 8), thus facilitating tumor specific binding/targeting (Figure 5-7) which can further provide a novel option for tumor specific probe development. The gene discussed is FASN; the disease is neoplasm.